产品
编 号：F743836
分子式：C14H15N3O5S
分子量：337.35
分子式：C14H15N3O5S
分子量：337.35
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 1293289-69-6
产品详情
生物活性：
TRC160334 is a hypoxia-inducible factor (HIF) hydroxylase inhibitor. TRC160334 can be used for the research of ischemia/reperfusion injury.
体内研究：
TRC160334 (0.1 and 0.3 mg/kg; i.p.) significantly reduces serum creatinine and blood urea nitrogen.TRC160334 (0.3 and 0.6 mg/kg; i.p.) shows reducing trends for acute tubular necrosis.TRC160334 significantly reduces the rise in electrolyte excretion dose dependently. Preischemic treatment with TRC160334 results in a pronounced induction of HSP70 in kidneys by 6 hours while postischemic treatment with TRC160334 results in a pronounced induction of HSP70 in kidneys by 12 hours as compared with the respective vehicle control.Animal Model:Sprague-Dawley male rats (250–300 g)
Dosage:0.1 and 0.3 mg/kg
Administration:I.p.
Result:Significantly reduced serum creatinine and blood urea nitrogen.
Animal Model:Sprague-Dawley male rats (250–300 g)
Dosage:0.3 and 0.6 mg/kg
Administration:I.p.
Result:Showed reducing trends for acute tubular necrosis.
体外研究：
TRC160334 (100~400 μΜ; 4 hours; Hep3B cells) results in dose-dependent stabilization of nuclear HIF-1.TRC160334 (75~300 μM; 4 hours; Hep3B cells) results in dose-dependent transcriptional activation of HIF-1. TRC160334 shows a dose-dependent expression of HIF target genes such as EPO and adrenomedullin.
TRC160334 is a hypoxia-inducible factor (HIF) hydroxylase inhibitor. TRC160334 can be used for the research of ischemia/reperfusion injury.
体内研究：
TRC160334 (0.1 and 0.3 mg/kg; i.p.) significantly reduces serum creatinine and blood urea nitrogen.TRC160334 (0.3 and 0.6 mg/kg; i.p.) shows reducing trends for acute tubular necrosis.TRC160334 significantly reduces the rise in electrolyte excretion dose dependently. Preischemic treatment with TRC160334 results in a pronounced induction of HSP70 in kidneys by 6 hours while postischemic treatment with TRC160334 results in a pronounced induction of HSP70 in kidneys by 12 hours as compared with the respective vehicle control.Animal Model:Sprague-Dawley male rats (250–300 g)
Dosage:0.1 and 0.3 mg/kg
Administration:I.p.
Result:Significantly reduced serum creatinine and blood urea nitrogen.
Animal Model:Sprague-Dawley male rats (250–300 g)
Dosage:0.3 and 0.6 mg/kg
Administration:I.p.
Result:Showed reducing trends for acute tubular necrosis.
体外研究：
TRC160334 (100~400 μΜ; 4 hours; Hep3B cells) results in dose-dependent stabilization of nuclear HIF-1.TRC160334 (75~300 μM; 4 hours; Hep3B cells) results in dose-dependent transcriptional activation of HIF-1. TRC160334 shows a dose-dependent expression of HIF target genes such as EPO and adrenomedullin.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备